BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Leukemia AND SRC, c-SRC, 6714, ENSG00000197122, P12931, ASV, p60-Src, SRC1, c-src AND Prognosis
54 results:

  • 1. Integrated bioinformatics analysis and network pharmacology to explore the potential mechanism of Patrinia heterophylla Bunge against acute promyelocytic leukemia.
    Feng L; Zhu S; Ma J; Hong Y; Wan M; Qiu Q; Li H; Li J
    Medicine (Baltimore); 2023 Oct; 102(40):e35151. PubMed ID: 37800842
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Focal adhesion kinase activation by calcium-dependent calpain is involved in chronic lymphocytic leukaemia cell aggressiveness.
    Severin F; Mouawad N; Ruggeri E; Visentin A; Martinello L; Pagnin E; Trimarco V; Pravato S; Angotzi F; Facco M; Trentin L; Frezzato F
    Br J Haematol; 2023 Oct; 203(2):224-236. PubMed ID: 37495265
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Optimal combination of immune checkpoint and senescence molecule predicts adverse outcomes in patients with acute myeloid leukemia.
    Wang P; Zhang Y; Cai Q; Long Q; Pan S; Zhou W; Deng T; Mo W; Wang S; Zhang Y; Wang C; Chen C
    Ann Med; 2023 Dec; 55(1):2201507. PubMed ID: 37070487
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Radotinib inhibits multiple myeloma cell proliferation via suppression of STAT3 signaling.
    Heo SK; Noh EK; Seo HJ; Lee YJ; Koh S; Min YJ; Choi Y; Jo JC
    PLoS One; 2022; 17(5):e0265958. PubMed ID: 35503759
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. GPX1-associated prognostic signature predicts poor survival in patients with acute myeloid leukemia and involves in immunosuppression.
    Zhang J; Peng Y; He Y; Xiao Y; Wang Q; Zhao Y; Zhang T; Wu C; Xie Y; Zhou J; Yu W; Lu D; Bai H; Chen T; Guo P; Zhang Q
    Biochim Biophys Acta Mol Basis Dis; 2022 Jan; 1868(1):166268. PubMed ID: 34536536
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. HSP90 inhibitor NVP-BEP800 affects stability of src kinases and growth of T-cell and B-cell acute lymphoblastic leukemias.
    Mshaik R; Simonet J; Georgievski A; Jamal L; Bechoua S; Ballerini P; Bellaye PS; Mlamla Z; Pais de Barros JP; Geissler A; Francin PJ; Girodon F; Garrido C; Quéré R
    Blood Cancer J; 2021 Mar; 11(3):61. PubMed ID: 33737511
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Targeting critical kinases and anti-apoptotic molecules overcomes steroid resistance in MLL-rearranged leukaemia.
    de Groot AP; Saito Y; Kawakami E; Hashimoto M; Aoki Y; Ono R; Ogahara I; Fujiki S; Kaneko A; Sato K; Kajita H; Watanabe T; Takagi M; Tomizawa D; Koh K; Eguchi M; Ishii E; Ohara O; Shultz LD; Mizutani S; Ishikawa F
    EBioMedicine; 2021 Feb; 64():103235. PubMed ID: 33581643
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Serum levels of FAK and some of its effectors in adult AML: correlation with prognostic factors and survival.
    El-Sisi MG; Radwan SM; Saeed AM; El-Mesallamy HO
    Mol Cell Biochem; 2021 May; 476(5):1949-1963. PubMed ID: 33507464
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Identification of the src-family tyrosine kinase HCK as a therapeutic target in mantle cell lymphoma.
    Lantermans HC; Minderman M; Kuil A; Kersten MJ; Pals ST; Spaargaren M
    Leukemia; 2021 Mar; 35(3):881-886. PubMed ID: 32591642
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. MLL-Rearranged Acute Lymphoblastic leukemia.
    El Chaer F; Keng M; Ballen KK
    Curr Hematol Malig Rep; 2020 Apr; 15(2):83-89. PubMed ID: 32350732
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Integrin α6 mediates the drug resistance of acute lymphoblastic B-cell leukemia.
    Gang EJ; Kim HN; Hsieh YT; Ruan Y; Ogana HA; Lee S; Pham J; Geng H; Park E; Klemm L; Willman CL; Carroll WL; Mittelman SD; Orgel E; Oberley MJ; Parekh C; Abdel-Azim H; Bhojwani D; Wayne AS; De Arcangelis A; Georges-Labouesse E; Wayner E; Bonig H; Minasyan A; Ten Hoeve J; Graeber TG; Müschen M; Heisterkamp N; Kim YM
    Blood; 2020 Jul; 136(2):210-223. PubMed ID: 32219444
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. PBX3 Promotes Tumor Growth and Angiogenesis via Activation of AT1R/VEGFR2 Pathway in Papillary Thyroid Carcinoma.
    Chen Q; Yu WY; Zhang HH; Zhang SZ; Fang J; Wu F; Ying HZ; Yu CH
    Biomed Res Int; 2020; 2020():8954513. PubMed ID: 32047817
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Expression of myeloid src-family kinases is associated with poor prognosis in AML and influences Flt3-ITD kinase inhibitor acquired resistance.
    Patel RK; Weir MC; Shen K; Snyder D; Cooper VS; Smithgall TE
    PLoS One; 2019; 14(12):e0225887. PubMed ID: 31790499
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Clinical significance of serum MicroRNA-203 in patients with acute myeloid leukemia.
    Guo Y
    Bioengineered; 2019 Dec; 10(1):345-352. PubMed ID: 31411110
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Phosphorylated STAT3 expression predicts better prognosis in smoldering type of adult T-cell leukemia/lymphoma.
    Morichika K; Karube K; Kayo H; Uchino S; Nishi Y; Nakachi S; Okamoto S; Morishima S; Ohshiro K; Nakazato I; Fukushima T; Masuzaki H
    Cancer Sci; 2019 Sep; 110(9):2982-2991. PubMed ID: 31237072
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Dasatinib and navitoclax act synergistically to target NUP98-NSD1
    Kivioja JL; Thanasopoulou A; Kumar A; Kontro M; Yadav B; Majumder MM; Javarappa KK; Eldfors S; Schwaller J; Porkka K; Heckman CA
    Leukemia; 2019 Jun; 33(6):1360-1372. PubMed ID: 30568173
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. The role of src family kinases in FLT3 signaling.
    Kazi JU; Rönnstrand L
    Int J Biochem Cell Biol; 2019 Feb; 107():32-37. PubMed ID: 30552988
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Effect of Tyrosin Kinase Inhibitors on NK Cell and ILC3 Development and Function.
    Damele L; Montaldo E; Moretta L; Vitale C; Mingari MC
    Front Immunol; 2018; 9():2433. PubMed ID: 30405627
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive.
    Garcia JS; Percival ME
    Drugs Today (Barc); 2017 Oct; 53(10):531-543. PubMed ID: 29286055
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Lck is a relevant target in chronic lymphocytic leukaemia cells whose expression variance is unrelated to disease outcome.
    Till KJ; Allen JC; Talab F; Lin K; Allsup D; Cawkwell L; Bentley A; Ringshausen I; Duckworth AD; Pettitt AR; Kalakonda N; Slupsky JR
    Sci Rep; 2017 Dec; 7(1):16784. PubMed ID: 29196709
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 3.